Treatment of patients suffering from EGFR-mutant cancers with EGFR inhibitors leads to objective response [1], [2], [3], to a doubling in progression-free survival as compared to standard chemotherapy and to long overall survival [4], [5]. Here, EGFR is linked to cancer.